Research programme: anti-cancer monoclonal antibody - Lundbeck Seattle BioPharmaceuticals Inc
Alternative Names: ALD806Latest Information Update: 24 Feb 2020
At a glance
- Originator Alder Biopharmaceuticals
- Developer Lundbeck Seattle BioPharmaceuticals Inc.
- Class Monoclonal antibodies
- Mechanism of Action Growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Oct 2019 Alder Biopharmaceuticals has been acquired by Lundbeck A/S